Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

Rofecoxib-d5

  • Zoom
    Rofecoxib-d<sub>5</sub>
  • Rofecoxib-d<sub>5</sub>
Cat No: 28900
Biochemicals - Isotopically Labeled Standards
Cayman

Rofecoxib-d5 is intended for use as an internal standard for the quantification of rofecoxib (Item No. 10010260) by GC- or LC-MS. Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2 over COX-1 with IC50 values o...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • 4-[4-(methylsulfonyl)phenyl]-3-(phenyl-d5)-2(5H)-furanone
Correlated keywords:
  • deuterated deuterium GCMS LCMS nonsteroidal antiinflammatory COX2 COX1 PGE 2 lipopolysaccharide mycobacterium MK-966 MK966 Vioxx BDD 11602 BDD11602
Product Overview:
Rofecoxib-d5 is intended for use as an internal standard for the quantification of rofecoxib (Item No. 10010260) by GC- or LC-MS. Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits COX-2 over COX-1 with IC50 values of 0.018 and >15 µM, respectively, for production of prostaglandin E2 (PGE2; Item No. 14010) in CHO cells expressing the recombinant human enzymes.{12018} In vivo, rofecoxib inhibits carrageenan-induced paw edema and hyperalgesia (ID50s = 1.5 and 1.0 mg/kg, respectively), LPS-induced pyresis (ID50 = 0.24 mg/kg), and M. butyricum-induced arthritis (ID50 = 0.74 mg/kg per day) in rats. Formulations containing rofecoxib were previously used in the treatment of pain and arthritis.
Size 500 µg
Shipping dry ice
CAS Number 544684-93-7
Molecular Formula C17H9D5O4S
SMILES O=C1OCC(C2=CC=C(S(C)(=O)=O)C=C2)=C1C3=C([2H])C([2H])=C([2H])C([2H])=C3[2H]
Molecular Weight 319,4
Formulation A solid
Purity ≥99% deuterated forms (d1-d5)
Custom Code 3822.19
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search